NCT07656376Not yet recruitingPhase 2
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
Jiangxi Kvvit Pharmaceutical Co., Ltd.0 sites465 target enrollmentStarted: June 6, 2027Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 465
Study Overview
Brief Summary
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Voluntarily signed informed consent form
- •Age 18-75 years (inclusive), male or female, at the time of signing informed consent
- •Life expectancy ≥ 12 weeks
- •Subjects with confirmed KRAS G12D who have not received prior systemic antineoplastic therapy for advanced or metastatic pancreatic cancer
- •ECOG score of performance status 0 ~ 1
- •At least one measurable lesion by RECIST v1.1 criteria
- •Adequate organ function
- •Effective methods of contraception during the study
Exclusion Criteria
- •Progression or other malignancy requiring treatment within 5 years prior to enrollment
- •Prior targeted therapy for KRAS G12D
- •With central nervous system metastasis
- •Uncontrolled fluid accumulation
- •Other anticancer therapy within 4 or 5 half-lives (whichever is shorter) before treatment
- •Concomitant clinically significant cardiovascular disease
- •Concurrent major acute or chronic infectious disease
- •4. Subjects who have undergone other major surgery other than diagnostic or biopsy, or are expected to undergo major surgery during the study;
- •History of severe mental or psychological illness or drug abuse or a history of severe alcohol abuse
- •Other situations not suitable for the study judged by the investigator
Investigators
Similar Trials
Not yet recruiting
Phase 1
DN022150 联合 AG 方案一线治疗携带 KRASG12D 基因突变的局晚期或转移性胰腺癌的临床试验（当前仅开展第一阶段试验）携带 KRASG12D 基因突变的、未经系统治疗的局晚期或转移性胰腺癌成人患者CTR20262207江西科睿药业有限公司
Active, not recruiting
Phase 3
HRS-4642 联合抗肿瘤药物治疗一线晚期胰腺癌晚期或转移性胰腺癌CTR20254212江苏恒瑞医药股份有限公司
Recruiting
Unknown
一项评价 QLC1101 联合用药治疗晚期实体瘤患者的临床研究晚期实体瘤CTR20251998齐鲁制药有限公司
Recruiting
Phase 2
RNK08954 片治疗 KRAS G12D 突变型转移性胰腺导管腺癌患者的 IIa 期临床研究转移性胰腺癌CTR20254089珃诺生物医药科技（杭州）有限公司
Completed
Phase 3
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)2024-511187-81-00Amgen Inc.99